PMID- 14674052
OWN - NLM
STAT- MEDLINE
DCOM- 20040217
LR  - 20191210
IS  - 0706-7437 (Print)
IS  - 0706-7437 (Linking)
VI  - 48
IP  - 10
DP  - 2003 Nov
TI  - Risk of weight gain associated with antipsychotic treatment: results from the 
      Canadian National Outcomes Measurement Study in Schizophrenia.
PG  - 689-94
AB  - BACKGROUND: Antipsychotic-induced weight gain occurs in a substantial percentage 
      of treated persons. There remains a paucity of naturalistic data that describe 
      relative weight-gain liability with the available novel atypical antipsychotics 
      (NAPs). This investigation describes comparative NAP-induced weight gain in a 
      prospective naturalistic cohort of persons with schizophrenia and related 
      psychotic disorders. METHODS: The Canadian National Outcomes Measurement Study in 
      Schizophrenia (CNOMSS) is an ongoing prospective, longitudinal, naturalistic 
      study involving 32 academic and community sites across Canada. Persons with 
      DSM-IV-defined schizophrenia, schizophreniform or schizoaffective disorder, and 
      psychosis not otherwise specified were consecutively enrolled. The overarching 
      objectives of this initiative were to collect and compare global effectiveness, 
      tolerability, safety, and humanistic outcomes in persons receiving commercially 
      available NAPs in Canada. This analysis reports only weight change with the 
      respective NAPs. Other outcomes were reported in separate companion papers. 
      RESULTS: A spectrum of weight-gain liability was noted with quetiapine (QUE) 
      (mean 7.55 kg, SD 9.20; P = 0.28), olanzapine (OLZ) (mean 3.72 kg, SD 0.56; P = 
      0.15), and risperidone (RIS) (mean 1.62 kg, SD 7.72; P = 0.43). Categorically 
      defined weight gain (that is, over 7% of baseline weight) was observed in 55.6% 
      of QUE patients, 24.1% of OLZ patients, and 23.7% of RIS patients. Adjusting for 
      demographic and disease-specific confounding factors, QUE patients had greater 
      odds of gaining over 7% of their baseline weight compared with RIS patients (odds 
      ratio [OR] 3.62; 95% CI, 1.02 to 12.83; P = 0.05). No statistical difference was 
      detected between OLZ patients and RIS patients for over 7% of baseline weight (OR 
      1.54; 95% CI, 0.63 to 3.75; P = 0.12) or over 10% weight gain (OR 1.44; 95% CI, 
      0.50 to 4.13; P = 0.58). CONCLUSION: Clinicians are reminded to monitor 
      anthropometric and metabolic parameters in all NAP-treated persons. Clinically 
      significant differences in weight gain liability exist among the available NAPs.
FAU - McIntyre, Roger S
AU  - McIntyre RS
AD  - Mood Disorders Psychopharmacology Clinic, Department of Psychiatry, University of 
      Toronto, University Health Network, Toronto Western Hospital, 399 Bathurst 
      Street, Toronto, ON M5T2S8. rmcintyr@uhnres.utoronto.ca
FAU - Trakas, Kostas
AU  - Trakas K
FAU - Lin, Daryl
AU  - Lin D
FAU - Balshaw, Robert
AU  - Balshaw R
FAU - Hwang, Pieway
AU  - Hwang P
FAU - Robinson, Kimberly
AU  - Robinson K
FAU - Eggleston, Andrew
AU  - Eggleston A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Can J Psychiatry
JT  - Canadian journal of psychiatry. Revue canadienne de psychiatrie
JID - 7904187
RN  - 0 (Antipsychotic Agents)
SB  - IM
MH  - Adult
MH  - Anthropometry
MH  - Antipsychotic Agents/administration & dosage/*adverse effects
MH  - Canada/epidemiology
MH  - Diagnostic and Statistical Manual of Mental Disorders
MH  - Drug Administration Schedule
MH  - Drug Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Obesity/*chemically induced/epidemiology
MH  - *Outcome Assessment, Health Care
MH  - Prospective Studies
MH  - Risk Factors
MH  - Schizophrenia/diagnosis/*drug therapy/epidemiology
MH  - Weight Gain/*drug effects
EDAT- 2003/12/17 05:00
MHDA- 2004/02/18 05:00
CRDT- 2003/12/17 05:00
PHST- 2003/12/17 05:00 [pubmed]
PHST- 2004/02/18 05:00 [medline]
PHST- 2003/12/17 05:00 [entrez]
AID - 10.1177/070674370304801008 [doi]
PST - ppublish
SO  - Can J Psychiatry. 2003 Nov;48(10):689-94. doi: 10.1177/070674370304801008.